Pancreas cancer harbors cells in different states, with classical cells (red) and basal cells (turquoise) co-existing within individual tumors. Basal cells, which typically are associated with aggressive disease, show increased sensitivity to KRAS inhibitors, a promising new drug class for pancreatic cancer.